Accessibility Menu
Arrow-Thin-Down
S&P 500
6,840.20
+0.3%
+17.86
Arrow-Thin-Down
DJI
47,562.87
+0.1%
+40.75
Arrow-Thin-Down
NASDAQ
23,724.96
+0.6%
+143.81
Arrow-Thin-Down
Bitcoin
$110,019.00
-0.3%
-$293.21
Arrow-Thin-Down
AAPL
$270.37
-0.4%
-$1.03
Arrow-Thin-Down
AMZN
$244.64
+9.8%
+$21.78
Arrow-Thin-Down
GOOG
$281.82
-0.0%
-$0.08
Arrow-Thin-Down
META
$648.35
-2.7%
-$18.12
Arrow-Thin-Down
MSFT
$518.14
-1.4%
-$7.62
Arrow-Thin-Down
NVDA
$202.49
-0.2%
-$0.40
Arrow-Thin-Down
TSLA
$456.60
+3.7%
+$16.50
Daily Stock GainersDaily Stock LosersMost Active Stocks
VolitionRx Stock Quote

VolitionRx (NYSEMKT: VNRX)

$0.42
(-2.4%)
-0.01
Price as of October 31, 2025, 3:43 p.m. ET

KEY DATA POINTS

Current Price
$0.43
Daily Change
(-2.4%) $0.01
Day's Range
$0.42 - $0.46
Previous Close
$0.43
Open
$0.44
Beta
0.82
Volume
501,727
Average Volume
480,309
Sector
Health Care
Market Cap
51.7M
Market Cap / Employee
$0.43M
52wk Range
$0.40 - $0.94
Revenue
-
Gross Margin
0.03%
Dividend Yield
N/A
EPS
-$0.24
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

VolitionRx Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VNRX-21.09%-85.39%-31.9%-86%
S&P+19.89%+109.18%+15.89%+492%

VolitionRx Company Info

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Financial Health

General

Q2 2025YOY Change
Revenue$0.41M2.8%
Gross Profit$0.09M22.4%
Gross Margin21.67%3.5%
Market Cap$78.30M56.1%
Market Cap / Employee$0.92M0.0%
Employees85-22.7%
Net Income-$6.31M10.6%
EBITDA-$5.98M10.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$2.26M-62.4%
Accounts Receivable$0.19M14.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$9.45M106.4%
Short Term Debt$1.49M16.3%

Ratios

Q2 2025YOY Change
Return On Assets-214.24%-54.6%
Return On Invested Capital-393.61%45.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$6.50M0.5%
Operating Free Cash Flow-$6.42M1.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-2.29-2.58-2.20-2.76-13.40%
Price to Sales41.0846.7442.0659.1415.46%
Price to Tangible Book Value-2.25-2.54-2.17-2.73-13.19%
Enterprise Value to EBITDA-9.42-10.81-11.23-14.2995.22%
Total Debt$5.89M$5.82M$7.37M$10.94M86.74%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services